1497: Predictive Value of Proliferative Inflammatory Atrophy (PIA) for Prostate Cancer on Repeat Prostate Biopsy

2006 ◽  
Vol 175 (4S) ◽  
pp. 483-483
Author(s):  
Charlie Jung ◽  
Michael S. Cookson ◽  
Matthew J. Putzi ◽  
Sam S. Chang ◽  
Joseph A. Smith ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Predictive Value ◽  
Proliferative Inflammatory Atrophy

MP-03.11 Predictive Value of Number of Cores with High-Grade PIN and Atypical Acinar Proliferation in Prostate Biopsy for the Diagnosis of Prostate Cancer

Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S44
Author(s):  
A.H. Arteche ◽  
L. San José Manso ◽  
L. Resel Folkersma ◽  
J. Casado Varela ◽  
M.E. Leon Rueda ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Predictive Value ◽  
High Grade

Meta-analysis of impact of circumcision and vitamin D on occurrence of prostate cancer: Could they act by suppressing anaerobes colonizing areas of prostatic proliferative inflammatory atrophy?

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 259-259
Author(s):  
R. Oliver
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Prostate Biopsy ◽  
Meta Analysis ◽  
Bacterial Flora ◽  
Sun Exposure ◽  
Life Time ◽  
Significant Excess ◽  
Hydroxyvitamin D ◽  
Proliferative Inflammatory Atrophy

259 Background: There is evidence that some false positive PSA tests can reflect prostatic inflammation that leads to Proliferative Inflammatory atrophy (PIA) that promotes malignant change. Report from circumcision trials in Africa suggest that dominant bacterial flora in un-circumcised men was anaerobes. As circumcised men have a lower incidence of PC this presentation reviews the literature on lack of circumcision and that on Vitamin D deficiency and as a cause of diminished host surveillance that could have potential to synergise as causes of PC. Methods: Three papers reporting incidence of PC in Jewish and non-Jewish men undergoing prostate biopsy for prostate symptoms and 7 series reporting case controlled studies published between 1952 and 2001 have provided data on circumcision and PC risk. There were 10 papers referred to in the IARC 2008 report on plasma 25-hydroxyvitamin D and PC. These have been reviewed together with 8 more published from 2008-10 and 3 that have examined impact of an index of life-time sun exposure on PC risk. Results: The 2 of 3 series of prostate biopsy reported 1951-65 demonstrated significant excess and 1 a non-significant excess of PC in the non-Jewish population. Of the 7 case controlled reported from 1971-2001, only 1 reported significant (OR 1.38) and 1 non-significant (OR 1.15) excess of lack of circumcision in those with prostate cancer, the remaining 6 studies having an excess cancer in those who have been circumcised (OR 0.50 – 0.82 pooled risk 0.70). Only 1 of the 18 plasma 25-OH Vit D series showed significant reduction of PC overall (6 did have reduction in prognostic subsets though 2 had higher incidence in the same sub-groups. In contrast all 3 series that have examined an index of life-time sun exposure showed significant reduction of PC (OR 0.18, 0.32 and 0.52 n= 850). Conclusions: The inconsistencies in the circumcision data suggest that it is not the surgery alone but the confounding variable of the hygiene rules that at least contribute to the reduced PC in Jewish men, and mirrors the similar differences seen in the protective value against AIDS of circumcision in Xhosa African and Asian Muslim men.

Elastography Targeted Prostate Biopsy in Patients under Active Surveillance

2020 ◽  
Vol 104 (11-12) ◽  
pp. 948-953
Author(s):  
Tobias Steinwender ◽  
Lukas Manka ◽  
Mircea Grindei ◽  
Zhe Tian ◽  
Alexander Winter ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Positive Predictive Value ◽  
Active Surveillance ◽  
Prostate Biopsy ◽  
Predictive Value ◽  
Individual Case ◽  
Cancer Center ◽  
Sensitivity Specificity ◽  
Targeted Biopsies

<b><i>Objective:</i></b> The aim of this study was to examine elastography-based prostate biopsy in prostate cancer (PCa) patients under active surveillance. <b><i>Patients and Methods:</i></b> We relied on PCa patients who opted for active surveillance and underwent elastography targeted and systematic follow-up biopsy at the Braunschweig Prostate Cancer Center between October 2009 and February 2015. Each prostate sextant was considered as an individual case. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy (ACC) for elastography to predict follow-up biopsy results were analyzed, respectively, and 95 % confidence intervals (CIs) were carried out by using 2000 bootstrapping sample analyses. <b><i>Results:</i></b> Overall, 50 men and 300 sextants were identified. Overall, 27 (54%) men and 66 (22%) sextants harbored PCa at follow-up biopsy. Sensitivity, specificity, PPV, NPV, and ACC for elastography to predict follow-up biopsy results were: 19.7 (95% CI: 11.9–27.3), 86.8 (95% CI: 82.7–90.3), 29.6 (95% CI: 14.6–46.0), 79.3 (95% CI: 71.6–86.5), and 72.0% (95% CI: 65.7–78.3), respectively. <b><i>Conclusions:</i></b> We recorded limited reliability of elastography-based prediction of follow-up biopsy results in active surveillance patients. Based on our analyses, we can neither recommend to rely exclusively on elastography-based targeted biopsies nor to delay or to omit follow-up biopsies based on elastography results during active surveillance.

UP-1.121: The Role of PSA in Diagnosis of Prostate Cancer: Does the Predictive Value of PSA Changes for the Secondary Prostate Biopsy?

Urology ◽  
2009 ◽  
Vol 74 (4) ◽  
pp. S208
Author(s):  
A. Cumpanas ◽  
M. Botoca ◽  
R. Minciu ◽  
M. Fahes ◽  
V. Bucuras ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Predictive Value

scholarly journals Predictive value of neutrophil-to-lymphocyte ratio in diagnosis of early prostate cancer among men who underwent Robotic transperineal prostate biopsy

2019 ◽  
Author(s):  
Du Jingzeng ◽  
Ee Jean Lim ◽  
Hong Hong Huang ◽  
Weber Kam On Lau
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Predictive Value ◽  
Full Blood Count ◽  
Diagnostic Purpose ◽  
Transperineal Prostate Biopsy ◽  
Cancer Group ◽  
Significant Difference ◽  
Benign Histology ◽  
Benign Group

Abstract Background： NLR is known to have prognostic value for metastatic prostate cancer. However for early-localized prostate cancer due to lack of systemic response; the role of NLR is not conclusive. In this study we aim to evaluate the predictive value of NLR for early clinical indolent prostate cancer in patients who underwent robotic transperineal prostate biopsy (RTPB). Methods: Patients who underwent RTPB under general anesthesia, at Urology Department, Singapore General Hospital between Sep 2006 and Feb 2016 were retrospectively reviewed. NLR was calculated for all patients using full blood count (FBC) that was done as pre-admission test before GA within 4 weeks before operation. And NLR values were compared between prostate cancer (PCa) and benign group. Results: A total 652 patients who underwent RTPB for diagnostic purpose with valid PSA level were included in this study. There were total 409 (62.7%) benign histology and 243 (37.3%) prostate cancer. There was no significant difference of median NLR between benign and prostate cancer group (2.00 vs. 1.99; P=0.29). In the subgroups analysis, there were also no significant difference of median NLR value in clinical significant cancer (defined as Gleason 3 + 4 and above) and benign histology group (NLR 2.00 vs. 2.01, P=0.41), as well as prostate cancer and benign group according to different pre-biopsy PSA levels: PSA (ug/l) < 4, 4-10,10-20 and > 20, respectively. (Median NLR 1.34 vs. 1.76; 1.97 vs. 1.97; 1.97 vs. 2.18; 2.18 vs. 1.98, P>0.05) Conclusion: There were no statistical significant difference of NLR between benign and prostate cancer group as a whole or in the subgroup analyses for patients who underwent robotic transperineal prostate biopsy. NLR may have a limited role in predicting early stage prostate cancer.

Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 96-96
Author(s):  
Derya Tilki ◽  
Daphne Hessels ◽  
Geert Trooskens ◽  
Susan Mulders ◽  
Michael Brawer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Validation Study ◽  
Prostate Biopsy ◽  
Predictive Value ◽  
Clinical Performance ◽  
Unmet Need ◽  
High Grade ◽  
Grade Group ◽  
Increased Risk ◽  
Average Serum

96 Background: There is an unmet need for non-invasive methods that can accurately identify patients at increased risk for clinically significant prostate cancer (PCa). SelectMDx is a urine-based molecular test that has been clinically validated for the detection of high-grade PCa. We evaluated SelectMDx clinical performance in a cohort of German men undergoing initial prostate biopsy. Methods: The study population consisted of 443 men sequentially enrolled men who underwent initial prostate biopsy between July 2009 and December 2014 due to suspected PCa. Post-DRE urine was collected from all subjects prior to biopsy, and samples stored at -70C. Urinary HOXC6 and DLX-1 mRNAs were quantified by PCR in May 2018, and RNA results combined with clinical risk factors to determine the likelihood that biopsy would identify ISUP grade group (GG) ≥ 2 (Gleason Score ≥ 7) PCa. We assessed SelectMDx performance for detection of GG ≥ 2 PCa, compared to the PCPT Risk Calculator Version 2.0 (PCPTRC, http://myprostatecancerrisk.com , accessed Oct 7, 2018). Results: For the 443 subjects enrolled, average age was 66 years (median 66, interquartile range 61 to 71), and average serum PSA level 8.8 ng/mL (6.4, 4.8 to 9.7). Cancer was detected in 243/443 (55%) men biopsied (43% GG1, 36% GG2, 9% GG3 and 12% GG4-5). The prevalence of GG2-5 PCa in this population was 31.4% (139/443). For detection of GG2 or higher PCa versus GG1 or no PCa at biopsy, SelectMDx AUC was 0.82 (95% C.I. 0.78-0.86) and the PCPTRC yielded AUC 0.75 (0.70-0.80), P < 0.001. SelectMDx sensitivity was 94% (89-98%), specificity 46% (40-52%), positive predictive value 45% (42-47%) and negative predictive value (NPV) 95% (90-97%). If the initial biopsy had been performed based on SelectMDx results alone, 46% of potentially unnecessary biopsies and 34% of all biopsies would have been avoided, while 5.8% of men with biopsy-detectable high-grade PCa (seven GG2, one GG3) may have had their diagnosis delayed. Conclusions: In this first validation study of SelectMDx in German men, the test’s clinical performance was comparable to the published EU validation study, showing a high NPV for detection of GG2 or higher PCa. These results provide further evidence for the clinical validity of SelectMDx.

Sign in / Sign up

Export Citation Format

Share Document